Dyslipidaemia Forecast in 12 Major Markets Report 2017-2027 - 10 Year Snapshot - Research and Markets
DUBLIN, Apr 5, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Dyslipidaemia Forecast in 12 Major Markets 2017-2027" report to their offering.
This report is built using data and information sourced from the proprietary patient segmentation database. To generate accurate patient population estimates, the database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Dyslipidaemia is defined as an abnormal amount of lipid(s) (triglycerides (>200), Low Density Lipoproteins (LDL) (>130), cholesterol (>240mg/dL) and High Density Lipoproteins (HDL)
- Stroke
- DVT
- Metabolic syndrome
- Heart failure
- T2DM
- Atherosclerosis
- Peripheral arterial disease
- Coronary Artery Disease
- Myocardial Infarction
- Elevated C-Reactive Protein
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Dyslipidaemia
10. Features of Dyslipidaemia patients
11. Abbreviations used in the report
12. Patient-Based Offering
13. Online Pricing Data and Platforms
14. References
15. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/fmwch3/dyslipidaemia
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article